A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy

Trial Profile

A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Plinabulin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to a BeyondSpring Pharmaceuticals media release, phase 1 data on the safety and mechanism of action of this regimen are expected in the first quarter of 2018, Enrollement in the phase 2 portion has recently commenced.
    • 29 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Mar 2018.
    • 21 Aug 2017 BeyondSpring anticipates initial safety data from this trial to be available in the second half of 2017, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top